17-18 September 2020
--- Virtual Meeting ---
Europe/Berlin timezone
+++ Registration Deadline: 24 August, 2020 at 11.59 pm (CEST) +++


last updated: 31 July 2020Follow us on Twitter @CCP2020HD

17 September, 4-9 pm (CEST)


Michael Baumann, German Cancer Research Center
Board member (tbc), German Cancer Aid

PSt Thomas Rachel, Federal Ministry of Research and Education
PSt'in Sabine Weiss, Federal Ministry of Health

Chair: Michael Baumann

 Introductory Lecture:  Elisabete Weiderpass, International Agency for Research on Cancer
Global cancer burden and research priorities for cancer prevention

Primary Cancer Prevention
Research in risk factors aiming for practical interventions
Chairs: Rudolf Kaaks & Thomas Seufferlein

 Keynote:  C. Richard Boland, University of California San Diego
Genetic mechanisms involved in colorectal tumor formation and the implications for prevention

Tilman Kühn, Queen's University Belfast
Obesity and cancer: From mechanisms and associations to prevention

Silvia de Sanjose (tbc), National Cancer Institute (consultant), PATH
Steps towards the control of cervical cancer in low resource settings

Rebecca Fitzgerald, University of Cambridge
Primary prevention of upper GI cancer

Olivera J. Finn, University of Pittsburgh
Vaccines for the prevention of colon and other non-viral cancers

Secondary Cancer Prevention
Prostate and Breast Cancer Screening
Chairs: Sebastian Bickelhaupt & Peter Albers

Keynote:  Monique J. Roobol, Erasmus University Medical Center
Prostate Cancer Screening – present and future perspectives

Heinz-Peter Schlemmer, German Cancer Research Center
Emerging imaging methods for early detection of breast and prostate cancer

Minetta Liu, Mayo Clinic Rochester
Novel molecular markers for early cancer detection

Rita Schmutzler, University Hospital Cologne
Challenges for increasingly personalized breast cancer screening and risk assessment


18 September, 4-9 pm (CEST)

Primary Cancer Prevention
Cancer Prevention in Europe
Chairs: Ute Mons

 Keynote:  Joachim Schüz, International Agency for Research in Cancer
The European Code against cancer

Isabelle Soerjomataram, International Agency for Research on Cancer
Alison Cox (tbc), Cancer Research UK

Secondary Cancer Prevention
Precision Prevention
Chairs: Ulrike Haug & Ulrike Peters

 Keynote:  Hormuzd Katki, National Cancer Institute
Risk Stratification in Lung Cancer Screening

Beatriz Carvalho, Netherlands Cancer Institute
Molecular risk classification of adenomas: Current knowledge and future potential in colorectal cancer early detection

Suzette Delaloge, Gustave Roussy, MyPeBs
Peter Albers, University Hospital Düsseldorf

Tertiary Cancer Prevention
Improving life with and after cancer
Chairs: Karen Steindorf & Hermann Brenner

 Keynote:  Jeffrey Meyerhardt, Dana-Farber Cancer Institute
The potential of tertiary prevention: the example of colorectal cancer

Lonneke van de Poll, Netherlands Cancer Institute
How to improve patient-centeredness of cancer care?

Julienne Bower, University of California Los Angeles
Biological mechanisms of cancer-related fatigue

Ben Schöttker, German Cancer Research Center
Role of co-medication in tertiary cancer prevention

Chair: Ernest Hawk

 Perspectives Lecture:  Timothy Rebbeck, Dana-Farber Cancer Institute
Cancer prevention and early detection in the precision medicine era

Closing Remarks
Michael Baumann, German Cancer Research Center


17 September, 5-7 pm (CEST)
Workshop: Secondary prevention of Prostate Cancer
Chairs: Peter Albers

Christian Arsov, University Hospital Düsseldorf
Lars Schimmöller, University Hospital Düsseldorf


Short biographies (A-Z)
- gradually being revealed
Follow us on Twitter @CCP2020HD

Julienne Bower
Dr. Julienne Bower is a Professor of Psychology and Psychiatry/Biobehav-ioral Sciences at the University of California Los Angeles (UCLA) and Research Scientist in the Cousins Center for Psychoneuroimmunology in the Semel Institute for Neuroscience and Human Behavior. Her research focuses broadly on bidirectional interactions between inflammation and psychologi-cal/behavioral states among individuals facing stressful life events. A central focus of her research has been understanding the biological mechanisms underlying fatigue and other behavioral disturbances in cancer patients and survivors. She has identified an inflammatory basis for cancer-related fatigue as well as biobehavioral risk factors for this symptom, including alterations in immune regulatory systems, cytokine gene polymorphisms, and early life stress. Another line of her research examines how stress influences physical health, with a focus on tumor biology, and resilience factors that may buffer the negative effects of stress exposure. Dr. Bower has also been actively involved in developing mind-body interventions for cancer populations and testing effects on psychological and immune outcomes.

Beatriz Carvalho
Beatriz Carvalho is a molecular biologist with a specific interest in colorectal adenoma to carcinoma progression and in the use of this knowledge for identification of better markers for early detection of colorectal cancer. After completing her PhD in 2001 in the area of gastric cancer she started a postdoctoral position in colorectal cancer, focusing on the biology of progression from adenoma to carcinoma, at the department of Pathology of the VU University Medical Center in Amsterdam. Since 2015, Dr. Carvalho has a senior scientist position at the Netherlands Cancer Institute (Amsterdam). The use of omics technology (DNA, RNA and protein level) facilitated the finding of several candidate genes putatively involved in colorectal progression, which are being followed up by in vitro functional studies using organoid culture systems. During the past years Dr. Carvalho has, next to understanding the biology of progression, worked also on the identification of biomarkers for early detection of colorectal cancer. One of the molecular drivers of adenoma-to-carcinoma progression is the occurrence of driver DNA copy number alterations, which can aid in the estimation of risk of progression and therefore be good intermediate endpoints in screening and/or surveillance of CRC. Dr. Carvalho is actively involved not only in the discovery but also in the validation of the research findings in order to translate these in the clinical setting.

Olivera J. Finn
Dr. Finn is University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair of the Department of Immunology. After receiving her PhD in Medical Microbiology at Stanford University in 1980 and completing her postdoctoral training in Immuno-oncology there in 1982, Dr. Finn started her research at Duke University and in 1991 moved to the University of Pittsburgh. She gained prominence through her basic and applied research on tumor antigens and cancer vaccines, in particular vaccines for the prevention of non-viral cancers, published in over 200 articles and over 70 reviews and book chapters. She serves on advisory boards of several cancer centers, including DKFZ, and on editorial boards of many cancer journals. Dr. Finn is member of the American Association of Immunologists (AAI) where she served as President in 2007/2008. She is a recipient of many awards and honors including the AAI Life Time Achievement Award, the NCI Outstanding Investigator Award, the AACR CIR Lloyd Old Cancer Immunology Prize and the SITC Smalley Award. She is AAI Distinguished Fellow.

Tilman Kühn
Tilman Kühn is a Lecturer in Nutritional Epidemiology at Queen’s University Belfast, with an adjunct position at the Heidelberg Institute of Global Health (HIGH). His research focus is on the effects of diet, body composition and metabolism in the development of cancer and chronic diseases. Many of his publications in this area are based on data from the EPIC-Heidelberg cohort that he worked on as a research assistant, post doc, and group head since 2010 in the Division of Cancer Epidemiology at DKFZ Heidelberg. Tilman is strongly interested in obesity prevention, and was the PI of the HELENA-Trial, a 2-year RCT to evaluate the metabolic effects and practicability of intermittent fasting among overweight persons. He is active in the German Society for Epidemiology (speaker, nutrition group) and the German Nutrition Society (guideline author, board member).

Minetta Liu
Minetta C. Liu, MD, is a breast medical oncologist and translational researcher at the Mayo Clinic in Rochester, MN, where she holds dual appointments in the Department of Oncology and the Department of Laboratory Medicine and Pathology. Her primary research focus is on the efficient advancement of novel therapeutics and the development of reliable predictors of systemic treatment response. As such, she leads several research trials with both clinical and correlative laboratory endpoints. She holds the academic rank of Professor of Oncology from the Mayo Clinic College of Medicine. Dr. Liu is Chair of Research for the Department of Oncology, Co-director of Genomics in Action for the Center for Individualized Medicine, a member of the Mayo Clinic Research Committee, Institutional Principal Investigator for the Translational Breast Cancer Research Consortium, Associate Medical Director for the Department of Development, and Medical Director for the Office of Specialty Contracts and Collaborations. She serves on the Breast Committee for the Alliance for Clinical Trials in Oncology, leads the Circulating Biomarker Working Group for the NIH Translational Research Program, and directs a laboratory focused on expanding the clinical applications and advancing the technologies related to liquid biopsies for solid tumors. She is dedicated to improving patient outcomes through access to novel therapeutic agents and molecular diagnostic tools.

Hormuzd Katki
Dr. Katki’s research focuses on understanding how epidemiologic findings could be used for cancer screening and prevention. He is particularly interested in developing individualized risk-based approaches to cancer screening. His methodologic research focuses on estimating individual absolute risk, strategies for risk-based screening and management, and metrics for evaluating risk models and biomarkers.

Lonneke van de Poll
Lonneke van de Poll-Franse is Professor of Cancer Epidemiology and Survivorship at Tilburg University and group leader at the department of Psychosocial research and Epidemiology at the Netherlands Cancer Institute in Amsterdam, The Netherlands. Her research focuses on quality of life and quality of care in the field of cancer survivorship. Lonneke has a special research interest in the impact of cancer and its treatment on patient reported outcomes (symptoms, health related quality of life) during cancer survivorship. In 2009, she started the PROFILES (Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship) registry that combines population-based cancer registry data with patient reported outcomes (www.profilesregistry.nl). She is an active member of the EORTC-QoL group and PI for the development of a lymphoma module and EORTC Cancer Survivorship questionnaire.

Timothy Rebbeck
Dr. Timothy Rebbeck is the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute. He is founding director of the Zhu Family Center for Global Cancer Prevention at the Harvard T.H. Chan School of Public Health and leads the Cancer Outreach and Engagement activities for the Dana-Farber Harvard Cancer Center. He leads molecular epidemiology studies to address problems of cancer etiology, prevention, outcomes, health disparities, and global health. His work has led to an understanding of the genetic and environmental causes of breast, prostate, skin, endometrial and ovarian cancers as well as interventions intended to reduce the burden of these cancers in individuals and populations. He founded and leads international cancer consortia that study risk and outcomes of 1) cancer in BRCA1/BRCA2 mutation carriers, and 2) prostate cancer in men of African descent in North America and Africa.

Rita Schmutzler
Rita Schmutzler is a specialist in Obstetrics and Gynecology, director of the Center for Familial Breast and Ovarian Cancer, University Hospital Cologne and co-ordinator of the German Consortium for Hereditary Breast and Ovarian Cancer. She is member of numerous committees such as the expert panel of the National Cancer Plan at the Federal Ministry of Health, the S3 guideline committee on breast cancer, the committee of the gene diagnostic act, the scientific advisory boards at the Federal Institute for Drugs and Medical Devices (BfArM) and the Institute for Quality and Efficiency in Health Care (IQWIG). Her main focus is to understand the hereditary basis of breast and ovarian cancer, identify genotype-/phenotype correlations and translate these findings into risk-adjusted clinical prevention programs.

Ben Schöttker
After his studies of pharmacy and the practical year he received the license as a pharmacist. In addition, he completed postgraduate Masters in "Public Health" and "Pharmacovigilance and Pharmacoepidemiology". After completing his doctorate at the Institute of Social Medicine at the University of Lübeck, he joined the Department of Clinical Epidemiology and Aging Research at the DKFZ in October 2009 for the postdoctoral phase and has been working in this position without interruption for 11 years now. Ben Schöttker is currently working in the area of pharmaco-epidemiology with a focus on the drug safety for elderly cancer patients.

Dr. Joachim Schüz
Dr. Joachim Schüz is a senior cancer epidemiologist. Since 2010, he is Head of the Section of Environment and Radiation at the International Agency for Research on Cancer (IARC), the cancer research agency of the World Health Organisation (WHO), in Lyon, France. Objectives of research in the Section are the identification of causes of cancer related to environmental pollutants, occupational exposures, some lifestyle factors, and radiations (ionizing and non-ionizing). In 2020, he additionally became Acting Head of the Section of Early Detection and Prevention at the IARC. Related to cancer prevention, Dr. Schüz is Chair of the newly established network “Cancer Prevention Europe”, a consortium of key cancer prevention institutions in Europe, and is leading the 4th edition of the European Code against Cancer. Before moving to the IARC, Dr. Schüz was working at the Danish Cancer Society Research Center in Copenhagen and at the University of Mainz, Germany, where he received his PhD in 1997 and his professorial qualifications (Habilitation) in 2002. Dr. Schüz worked in the field of cancer epidemiology throughout his career.

Elisabete Weiderpass,
Elisabete Weiderpass, MD, MSc, PhD, is a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In January 2019, Dr. Weiderpass took office as elected Director of the International Agency for Research on Cancer (IARC, www.iarc.fr), the specialized cancer agency of the World Health Organization (WHO), based in Lyon, France. The Agency welcomes about 350 staff dedicated to cancer research. Its membership and governance is made up of 27 countries (or ‘participating States’), including Germany. Dr. Weiderpass previously served as Head of the Department of Research at the Cancer Registry of Norway, and of the Genetic Epidemiology Group at the Folkhälsan Research Center in Finland. She was a Professor of Medical Epidemiology at the Karolinska Institutet in Stockholm, Sweden, and a Professor of Cancer Epidemiology at the Arctic University of Norway. She held Adjunct Professorship positions in Cancer Epidemiology in Brazil, China, and the Islamic Republic of Iran, and is a Visiting Professor in Kuwait. Dr. Weiderpass has authored over 800 scientific publications in peer-reviewed international journals.

Organized by

Supported by